Livingston, NJ, United States of America

Chung-Bin Kim

This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 1990.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Chung-Bin Kim

Introduction

Chung-Bin Kim is an accomplished inventor based in Livingston, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of analgesic formulations. His work has led to advancements that enhance the effectiveness of pain relief medications.

Latest Patents

Chung-Bin Kim holds a patent for an analgesic tablet that combines aspirin, acetaminophen, and caffeine. This innovative formulation is designed to improve the dissolution rate of the active ingredients by incorporating low-substituted hydroxypropylcellulose. This patent represents a notable achievement in the quest for more effective pain relief solutions.

Career Highlights

Chung-Bin Kim is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role at Bristol-Myers Squibb allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative drug formulations.

Collaborations

Chung-Bin Kim collaborates with Thomas M. Tencza, a fellow professional in the pharmaceutical industry. Their partnership exemplifies the importance of teamwork in driving innovation and achieving breakthroughs in drug development.

Conclusion

Chung-Bin Kim's contributions to the field of pharmaceuticals, particularly through his patent for an improved analgesic tablet, highlight his dedication to enhancing pain relief options. His work at Bristol-Myers Squibb and collaboration with colleagues further underscore his impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…